Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET
XIANYANG,
Pharmaceuticals, Inc. (Nasdaq: BSPM) (“Biostar” or “the Company”), a Xianyang-
based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin
Aoxing Oleanolic Acid Capsules (“Xin Aoxing”), and a variety of pharmaceutical
products, today announced that management will hold a conference call to
discuss its 2010 first quarter performance at
2010
closes.
Interested parties may access the call by dialing +1-877-941-4775 from
within
conference ID is 4302147. It is advisable to dial in approximately 5-10
minutes prior to the start of the call.
A playback will be available through
800-406-7325 within
internationally. Utilize the pass code 4302147 for the replay.
This call is being web cast by ViaVid Broadcasting and can be accessed at
ViaVid’s website at http://www.viavid.net or at the following link:
http://viavid.net/dce.aspx?sid=00007582 . To access the web cast, you will
need to have the Windows Media Player on your desktop. For the free download
of the Media Player please visit:
http://www.microsoft.com/windows/windowsmedia/en/download/default.asp .
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary in
variety of diseases and conditions. The Company’s most popular product is its
Xin Aoxing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for
chronic hepatitis B, a disease affecting approximately 10% of the Chinese
population. In addition to its hepatitis product, Biostar manufactures two
broad-based OTC products and two prescription-based pharmaceuticals. The
Company has adopted international standards, holds one patent and is in the
process of applying for two patents.
Safe Harbor
Certain statements in this release concerning our future growth prospects
are forward-looking statements, within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended, which involve a number of risks and
uncertainties that could cause actual results to differ materially from those
in such forward-looking statements. The risks and uncertainties relating to
these statements include, but are not limited to, risks and uncertainties
regarding the success of our investments, risks and uncertainties regarding
fluctuations in earnings, our ability to sustain our previous levels of
profitability including on account of our ability to manage growth, intense
competition, wage increases in
skilled professionals, time and cost overruns on fixed-price, fixed-time frame
contracts, client concentration, our ability to successfully complete and
integrate potential acquisitions, withdrawal of governmental fiscal incentives,
political instability and regional conflicts and legal restrictions on raising
capital or acquiring companies outside
affect our future operating results are more fully described in our United
States Securities and Exchange Commission filings including our S-1 dated
27, 2008
2009
These filings are available at http://www.sec.gov . We may, from time to time,
make additional written and oral forward-looking statements, including
statements contained in our filings with the Securities and Exchange
Commission and our reports to shareholders. We do not undertake to update any
forward-looking statements that may be made from time to time by or on our
behalf.
For further information, please contact:
Ms. Elaine Zhao, CFO
Tel: +1-626-456-2789
Email: elainezhao@biostarpharmaceuticals.com
John Mattio
HC International, Inc.
Tel: US +1-914-669-5340
Email: john.mattio@hcinternational.net
Web: http://www.hcinternational.net
SOURCE Biostar Pharmaceuticals, Inc.